Evidence map›Paper›PMID 38020616›Full record

SynthesisFrontiers in neurology2023

Effect of magnesium sulfate on cerebral vasospasm in the treatment of aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Hanlin Zheng, Xiumei Guo, Xinyue Huang, Yu Xiong, Wen Gao, Chuhan Ke, Chunhui Chen, Zhigang Pan, Lichao Ye, Lingxing Wang and 2 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hanlin Zheng *Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Xiumei Guo *Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Xinyue Huang *Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Yu Xiong *Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Wen GaoDepartment of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Chuhan KeDepartment of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Chunhui ChenDepartment of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Zhigang PanDepartment of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Lichao YeDepartment of Neurology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Lingxing WangDepartment of Neurology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Weipeng HuDepartment of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Feng ZhengDepartment of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Fujian Medical University · CNSecond Affiliated Hospital of Fujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The use of magnesium sulfate for treating aneurysmal subarachnoid hemorrhage (aSAH) has shown inconsistent results across studies. To assess the impact of magnesium sulfate on outcomes after aSAH, we conducted a systematic review and meta-analysis of relevant randomized controlled trials. Methods: PubMed, Embase, and the Cochrane Library were searched for relevant literature on magnesium sulfate for aSAH from database inception to March 20, 2023. The primary outcome was cerebral vasospasm (CV), and secondary outcomes included delayed cerebral ischemia (DCI), secondary cerebral infarction, rebleeding, neurological dysfunction, and mortality. Results: Of the 558 identified studies, 16 comprising 3,503 patients were eligible and included in the analysis. Compared with control groups (saline or standard treatment), significant differences were reported in outcomes of CV [odds ratio (OR) = 0.61, Conclusion: The superiority of magnesium sulfate over standard treatments for CV, DCI, secondary cerebral infarction, and neurological dysfunction in patients with aSAH was demonstrated. Further randomized trials are warranted to validate these findings with increased sample sizes.

Indexed as

aneurysmal subarachnoid hemorrhagecerebral vasospasmdelayed cerebral ischemiamagnesium sulfatemortalityneurological dysfunctionrebleedingsecondary cerebral infarction

Identifiers

PMID38020616
PMCPMC10668149
OpenAlexW4388631308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.